Status:
COMPLETED
Physiologic Monitoring of Antidepressant Response
Lead Sponsor:
University of California, Los Angeles
Conditions:
Major Depression
Eligibility:
All Genders
18-65 years
Phase:
PHASE4
Brief Summary
Primary: to identify physiologic indicators of venlafaxine treatment response using quantitative EEG (QEEG) cordance, and to determine if cordance changes are specifically associated with response to ...
Detailed Description
After a one-week single-blind placebo lead in, subjects will be randomly assigned to either venlafaxine or placebo for 8 weeks. They will undergo 6 QEEG studies (end of wash-in, and 48 hours, 1 week, ...
Eligibility Criteria
Inclusion
- All subjects will meet DSM-IV criteria for depression on the basis of a SCID-P interview, with subjects in the placebo controlled phase of the study having a score on the 17-item Ham-D \> 18 (with item #1 \> 2). Subjects will meet criteria both at recruitment, and after a one-week single blind placebo wash-in. - Study includes outpatients only.
Exclusion
- All subjects will have no serious medical illness.
- The investigators will exclude patients also meeting criteria for the following groups of axis I diagnoses:
- delirium or dementia
- substance-related disorders
- schizophrenia or other psychotic disorders
- eating disorders.
- In addition, patients meeting criteria for cluster A or B axis II diagnoses will be excluded.
- Subjects with a history of current or past active suicidal ideation, or suicide attempts will be excluded from the placebo-controlled phase of the study.
Key Trial Info
Start Date :
November 1 1996
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 1998
Estimated Enrollment :
38 Patients enrolled
Trial Details
Trial ID
NCT00792168
Start Date
November 1 1996
End Date
December 1 1998
Last Update
December 22 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of California
Los Angeles, California, United States, 90024